Get the Stockscreener App
23.90
0.58%
-0.14
After Hours:
23.90
Travere Therapeutics Inc stock is traded at $23.90, with a volume of 1.86M.
It is down -0.58% in the last 24 hours and up +36.57% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$24.04
Open:
$24.08
24h Volume:
1.86M
Relative Volume:
0.95
Market Cap:
$2.13B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-11.72
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
-1.36%
1M Performance:
+36.57%
6M Performance:
+33.37%
1Y Performance:
+70.84%
1-Day Range:
$23.61
$24.39
1-Week Range:
$22.05
$25.48
52-Week Range:
$12.91
$28.69
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
23.90 | 2.14B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
391.64 | 101.35B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.00 | 58.66B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
562.27 | 59.43B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
737.56 | 44.01B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
340.70 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
How to use a screener to detect Travere Therapeutics Inc. breakoutsGap Up & Risk Controlled Stock Alerts - newser.com
Travere Therapeutics (NASDAQ:TVTX) Trading Down 7.6%What's Next? - MarketBeat
Published on: 2025-09-29 13:53:58 - newser.com
Published on: 2025-09-29 12:50:11 - newser.com
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Using data tools to time your Travere Therapeutics Inc. exitJuly 2025 Setups & Safe Swing Trade Setup Alerts - newser.com
Can trapped investors hope for a rebound in Travere Therapeutics Inc.Weekly Trade Analysis & Proven Capital Preservation Tips - newser.com
Heatmap analysis for Travere Therapeutics Inc. and competitorsPortfolio Value Summary & Weekly Watchlist of Top Performers - newser.com
Travere therapeutics CEO Eric M. Dube sells $273,455 in stock - MSN
Is GAIL India Limited One of the Top Picks for Growth Investors in YEARFlag and Pennant Patterns & Free Phenomenal Trading Returns - earlytimes.in
Published on: 2025-09-28 13:45:23 - earlytimes.in
Published on: 2025-09-28 02:30:57 - newser.com
Travere Therapeutics Inc Stock Analysis and ForecastMarket Profile Overview & Double Digit Returns - earlytimes.in
Travere Therapeutics Forms Golden Cross, Signaling Bullish Breakout Ahead - Markets Mojo
CSL Vifor and Travere Therapeutics Recognize Updated KDIGO Clinical Practice Guidelines for IgA Nephropathy - Sharecast News
Insider Selling: Travere Therapeutics (NASDAQ:TVTX) Insider Sells 10,000 Shares of Stock - MarketBeat
Travere Therapeutics' (TVTX) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Wall Street Zen Downgrades Travere Therapeutics (NASDAQ:TVTX) to Hold - MarketBeat
Travere Therapeutics, Inc. $TVTX Shares Acquired by Assenagon Asset Management S.A. - MarketBeat
H.C. Wainwright reiterates Buy rating on Travere Therapeutics stock - Investing.com
Travere Therapeutics (NASDAQ:TVTX) Downgraded by Wall Street Zen to “Hold” - Defense World
Travere Therapeutics (TVTX): Evaluating Valuation After FDA Fast-Track and Positive FILSPARI Study Results - Sahm
Travere Therapeutics (NASDAQ:TVTX) Earns Buy Rating from HC Wainwright - Defense World
Travere Therapeutics Inc. stock momentum explainedJuly 2025 Review & Long Hold Capital Preservation Plans - newser.com
Sector ETF performance correlation with Travere Therapeutics Inc.July 2025 Technicals & Community Supported Trade Ideas - newser.com
MACD Signal: How sensitive is Travere Therapeutics Inc. to inflation2025 Winners & Losers & Free Reliable Trade Execution Plans - خودرو بانک
HC Wainwright & Co. Reiterates Buy Rating for Travere Therapeuti - GuruFocus
Trading Action: Does Travere Therapeutics Inc. stock have upside surprise potential2025 Investor Takeaways & Reliable Volume Spike Trade Alerts - خودرو بانک
Whale Trades: Can Travere Therapeutics Inc. be the next market leaderWeekly Gains Report & Risk Managed Investment Signals - خودرو بانک
Nephrotic Syndrome Market Analysis: Epidemiology Insights, Therapies, Companies, DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers - Barchart.com
Can Travere Therapeutics Inc be the next market leaderQuarterly Growth Report & Breakout Confirmation Alerts - khodrobank.com
Travere Therapeutics Inc. stock outlook for YEARPortfolio Risk Summary & Real-Time Volume Trigger Notifications - newser.com
Stifel Nicolaus Increases Travere Therapeutics (NASDAQ:TVTX) Price Target to $25.00 - MarketBeat
Travere Therapeutics (NASDAQ:TVTX) Given New $35.00 Price Target at Wells Fargo & Company - MarketBeat
Live market analysis of Travere Therapeutics Inc.Weekly Risk Report & Community Consensus Picks - newser.com
Travere rises as FDA says no AdCom required for Filspari label expansion - MSN
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA - MSN
FDA Drops Advisory Committee for Travere’s FILSPARI Review - MSN
Woodline Partners LP Sells 884,278 Shares of Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics (TVTX) Awaits FDA Decision as FILSPARI Shows Promising Clinical Results - Sahm
Signal Recap: Whats the analyst consensus on Travere Therapeutics IncExit Point & Safe Entry Zone Identification - خودرو بانک
Quarterly Recap: Is Travere Therapeutics Inc.’s growth already priced in2025 Retail Activity & Stepwise Swing Trade Plans - خودرو بانک
Highs Report: Is Travere Therapeutics Inc subject to activist investor interestDay Trade & Free Long-Term Investment Growth Plans - خودرو بانک
Institution Moves: What is Travere Therapeutics Incs debt to equity ratioGDP Growth & Stock Market Timing Techniques - خودرو بانک
Aug Highlights: How liquid is Travere Therapeutics Inc stockJuly 2025 Price Swings & Stock Market Timing Techniques - خودرو بانک
Short Covering: Is Cuprina Holdings Cayman Limited a turnaround storyTrade Entry Report & AI Enhanced Execution Alerts - khodrobank.com
Travere Therapeutics Stock Soars Pre-market After FDA Waives Need For An Advisory Committee Meeting On Its Kidney Disorder Drug Application - MSN
Travere Therapeutics (TVTX) Is Up 8.5% After FDA Removes Advisory Panel Step for FILSPARI in FSGS - Sahm
Travere Therapeutics (NASDAQ:TVTX) Shares Down 4.8%Should You Sell? - MarketBeat
Travere Therapeutics Sees Unusually Large Options Volume (NASDAQ:TVTX) - MarketBeat
Polar Asset Management Partners Inc. Invests $304,000 in Travere Therapeutics, Inc. $TVTX - MarketBeat
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):